Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
1 2 3 4 5 … Next › Last »

ICER Panel Endorses Value Of Vertex’ Journavx Compared To Opioids, But Questions Benefits Compared To NSAIDs; Coverage Policies Will Be Key To Uptake

March 7, 2025

Prevision Policy Clips | FDA Commissioner Nominee Makary Breezes Through Senate Hearing

March 7, 2025

VRBPAC Will Be Back, But Maybe Not For Flu, FDA Commissioner Nominee Makary Says; Is Another Advisory Committee Reset Coming?

March 7, 2025

Generics, Biosimilars – And OTCs – Are Part Of FDA Role In Drug Pricing Policy, Commissioner Nominee Makary Says

March 6, 2025

FDA Nominee Makary Promises “Surgical” Approach To FDA Cuts – But No Guarantee He Will Be Wielding The Scalpel; “MAHA” Themes Coming To FDA, But Toned Down From RFK

March 6, 2025

Prevision Policy Clips | Trump’s 10-To-1 Deregulation Policy Will Force FDA To Give “Care And Consideration”

March 6, 2025

Drug Pricing, Researcher Conflicts Of Interest With Big Pharma Get Attention During NIH Nominee Bhattacharya’s Senate HELP Confirmation Hearing

March 5, 2025

Prevision Policy Clips | Trump Praises MAHA Commission, Announces “Reciprocal Tariffs” On April 2

March 5, 2025

Prevision Policy Clips | Drug Prices, Pharma Tariffs And Medicaid Cuts Are Topics To Watch For During President Trump's Address

March 4, 2025

Prevision Policy Clips | FDA Return To Office Procedures Are Underway; Initial Process Is Relatively Smooth

March 3, 2025

Controlled Correspondence: FDA Encourages Generic Sponsors To Ask Better Questions; SBIA Event Includes Plea For Industry To Affirm Value Of FDA Public Meetings

February 28, 2025

FDA Deadline Tracker: No Sign Of Slippage On Drug Reviews In First Month Under Trump

February 28, 2025

Prevision Policy Clips | FDA Commissioner Nominee Makary Set For March 6 Confirmation Hearing

February 28, 2025

Advisory Committee Tracker: FDA Resumes Public Speaking Engagements – But Advisory Committees Still MIA

February 27, 2025

PRV Renewal, PBM Reform Are Bipartisan Issues At House Health Subcommittee Hearing But Pathway Is “Uncertain”

February 27, 2025

FDA’s Next DOGE Test: How Will “Maximum” Cuts Be Defined For Agency Under OMB Memo Implementing Trump Executive Order

February 27, 2025

Prevision Policy Clips | DOGE Phase 2: OMB Guidance Calls For Agency RIF And Reorganization Plans (ARRP) By March 13

February 27, 2025

Cell Therapy Regulatory Revamp Could Mirror Device Regulations: A Risk-Based System Would Encourage Development And Discourage “Bad Actors,” CBER Says

February 26, 2025

Prevision Policy Clips | FDA Shutters Clozapine REMS

February 26, 2025

FDA Drug/Biologic Review Largely Insulated From DOGE RIFs So Far; Communications Freeze (Sort Of) Lifted

February 25, 2025

GLP-1 Pushback? HHS Inspector General Flags Surging Use Of Anti-Diabetics, Suggests Scripts May Be Outside “Medically Accepted Indications”

February 25, 2025

Prevision Policy Clips | CBER’s Marks And Verdun Deliver Opening Remarks At HCT/P Workshop

February 25, 2025

House Energy & Commerce Committee Plans To Highlight Downsides Of Price Negotiation In 119th Congress; Domestic Manufacturing, Chronic Diseases Among Other Topics On Oversight Agenda

February 24, 2025

Prevision Policy Clips | Medicare Price Negotiation: CMS Sets Dates For Roundtable, Town Hall Events

February 24, 2025

FDA Retirements And Departures: CDER Changes Include Departures Of Pain Medicine, Non-Malignant Hematology Division Leaders; CBER Deputy Witten Has Retired

February 21, 2025
1 2 3 4 5 … Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Copyright © 2025 Prevision Policy. All Rights Reserved. Privacy Policy